Oncolytic viruses: a novel form of immunotherapy

References

• Aghi M, Martuza RL. Oncolytic viral therapies – the clinical experience. Oncogene24(52), 7802–7816 (2005).
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer5(12), 965–976 (2005).
   PubMed Web of Science ®Google Scholar
• Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther.8(2), 89–98 (2001).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Hatfield P et al. The immune system – is it relevant to cancer development, progression and treatment? Clin. Oncol. (R. Coll. Radiol.)20(2), 101–112 (2008).
   PubMed Web of Science ®Google Scholar
• Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother.54(3), 187–207 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature411(6835), 380–384 (2001).
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol.12, 991–1045 (1994).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol.13(1), 114–119 (2001).
   PubMed Web of Science ®Google Scholar
• de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer6(1), 24–37 (2006).
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature445(7128), 656–660 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med.10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Diaz RM, Galivo F, Kottke T et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res.67(6), 2840–2848 (2007).
   PubMed Web of Science ®Google Scholar
• Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res.60(20), 5714–5722 (2000).
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Conejo Garcia JR et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol. Ther.12(5), 789–802 (2005).
   PubMed Web of Science ®Google Scholar
• Moehler MH, Zeidler M, Wilsberg V et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther.16(8), 996–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin. Exp. Immunol.146(2), 344–353 (2006).
   PubMedGoogle Scholar
• Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M. T cell immunity induced by live, necrotic, and apoptotic tumor cells. J. Immunol.173(2), 1012–1022 (2004).
   PubMedGoogle Scholar
• Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces “danger signals” upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology210(5), 295–303 (2005).
   PubMed Web of Science ®Google Scholar
• Endo Y, Sakai R, Ouchi M et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene27(17), 2375–2381 (2008).
   PubMed Web of Science ®Google Scholar
• Aliberti J, Viola JP, Vieira-de-Abreu A, Bozza PT, Sher A, Scharfstein J. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J. Immunol.170(11), 5349–5353 (2003).
   PubMed Web of Science ®Google Scholar
• Ichim CV. Revisiting immunosurveillance and immunostimulation: implications for cancer immunotherapy. J. Transl. Med.3(1), 8 (2005).
   PubMed Web of Science ®Google Scholar
• Errington F, White CL, Twigger KR et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther.15(18), 1257–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol.25(2), 75–84 (2004).
   PubMed Web of Science ®Google Scholar
• Detournay O, Mazouz N, Goldman M, Toungouz M. IL-6 produced by type I IFN DC controls IFN-γ production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum. Immunol.66(5), 460–468 (2005).
   PubMed Web of Science ®Google Scholar
• Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity27(3), 370–383 (2007).
   PubMed Web of Science ®Google Scholar
• Kalinski P, Giermasz A, Nakamura Y et al. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol. Immunol.42(4), 535–539 (2005).
   PubMed Web of Science ®Google Scholar
• Errington F, Steele L, Prestwich R et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol.180(9), 6018–6026 (2008).
   PubMed Web of Science ®Google Scholar
• Jenne L, Hauser C, Arrighi JF, Saurat JH, Hugin AW. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther.7(18), 1575–1583 (2000).
   PubMed Web of Science ®Google Scholar
• Grosjean I, Caux C, Bella C et al. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. J. Exp. Med.186(6), 801–812 (1997).
   PubMed Web of Science ®Google Scholar
• Schierer S, Hesse A, Muller I et al. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Int. J. Cancer122(1), 219–229 (2008).
   PubMedGoogle Scholar
• Stojdl DF, Lichty BD, tenOever BR et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4(4), 263–275 (2003).
   PubMed Web of Science ®Google Scholar
• Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature433(7028), 887 (2005).
   PubMed Web of Science ®Google Scholar
• Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol.9(5), 558–566 (2008).
   PubMed Web of Science ®Google Scholar
• Turley SJ, Inaba K, Garrett WS et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science288(5465), 522–527 (2000).
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science299(5611), 1400–1403 (2003).
   PubMed Web of Science ®Google Scholar
• Qiao J, Kottke T, Willmon C et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med.14(1), 37–44 (2008).
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther.10(3), 385–393 (1999).
   PubMed Web of Science ®Google Scholar
• Li H, Dutuor A, Fu X, Zhang X. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J. Gene Med. 9(3), 161–169 (2007).
   PubMed Web of Science ®Google Scholar
• Li H, Dutuor A, Tao L, Fu X, Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res.13(1), 316–322 (2007).
   PubMed Web of Science ®Google Scholar
• Miller CG, Fraser NW. Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol. Ther.7(6), 741–747 (2003).
   PubMedGoogle Scholar
• Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int. J. Oncol.31(5), 1009–1019 (2007).
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Ilett EJ et al.Tumor infection by oncolytic reovirus primes adaptive anti-tumor immunity. Clin. Cancer Res. (2008) (In press).
   PubMedGoogle Scholar
• Ikeda K, Wakimoto H, Ichikawa T et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol.74(10), 4765–4775 (2000).
   PubMed Web of Science ®Google Scholar
• Ikeda K, Ichikawa T, Wakimoto H et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5(8), 881–887 (1999).
   PubMed Web of Science ®Google Scholar
• Tsai V, Johnson DE, Rahman A et al. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin. Cancer Res.10(21), 7199–7206 (2004).
   PubMedGoogle Scholar
• Lyons M, Onion D, Green NK et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther.14(1), 118–128 (2006).
   PubMed Web of Science ®Google Scholar
• Green NK, Herbert CW, Hale SJ et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther.11(16), 1256–1263 (2004).
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther.13(15), 1887–1900 (2002).
   PubMed Web of Science ®Google Scholar
• Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V. Selective gene transfer to tumor cells by recombinant Newcastle disease virus via a bispecific fusion protein. Int. J. Oncol.26(2), 431–439 (2005).
   PubMedGoogle Scholar
• Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther.6(2), 215–226 (2006).
   PubMed Web of Science ®Google Scholar
• Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther.15(10), 772–779 (2008).
   PubMed Web of Science ®Google Scholar
• Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science311(5768), 1780–1784 (2006).
   PubMed Web of Science ®Google Scholar
• Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res.62(21), 6070–6079 (2002).
   PubMed Web of Science ®Google Scholar
• Hu JC, Coffin RS, Davis CJ et al. A Phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res.12(22), 6737–6747 (2006).
   PubMed Web of Science ®Google Scholar
• Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther.6(5), 409–422 (1999).
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol.9(6), 533–542 (2008).
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol.20(20), 4181–4190 (2002).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother.54(6), 587–598 (2005).
   PubMed Web of Science ®Google Scholar
• White CL, Twigger KR, Vidal L et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a Phase I clinical trial. Gene Ther.15(12), 911–920 (2008).
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res.14(1), 259–269 (2008).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J. Immunol.34(2), 336–344 (2004).
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol.6(5), 383–393 (2006).
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther.15(8), 604–616 (2008).
   PubMed Web of Science ®Google Scholar
• Kottke T, Galivo F, Wongthida P et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther.16(7), 1217–1226 (2008).
   PubMed Web of Science ®Google Scholar
• Thorne SH, Hwang TH, O’Gorman WE et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest.117(11), 3350–3358 (2007).
   PubMed Web of Science ®Google Scholar
• Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-β to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med.4(12), E353 (2007).
   PubMed Web of Science ®Google Scholar
• Twigger K, Vidal L, White CL et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin. Cancer Res.14(3), 912–923 (2008).
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol.174(12), 7516–7523 (2005).
   PubMed Web of Science ®Google Scholar
• Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med.203(5), 1259–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res.63(15), 4490–4496 (2003).
   PubMed Web of Science ®Google Scholar
• Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother.30(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar